Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung

Toxicology and Applied Pharmacology

Volumn 215, Issue 1, 2006, Pages 100-108

  Dailey, L A ^a   Jekel, N ^b   Fink, L ^b   Gessler, T ^b   Schmehl, T ^b   Wittmar, M ^a   Kissel, T ^a   Seeger, W ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Biodegradable; Inflammation; Nanoparticles; Polymer; Polystyrene

Indexed keywords

DIETHYLAMINOPROPYLAMINE POLYVINYL ALCOHOL; GLUCOSE; LACTATE DEHYDROGENASE; MESSENGER RNA; NANOPARTICLE; POLYGLACTIN; POLYSTYRENE; POLYVINYL DERIVATIVE; PROTEIN; PROTEIN MIP 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADATION; CELL POPULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; HYDRODYNAMICS; LUNG; MOUSE; MOUSE STRAIN; NEUTROPHIL; NONHUMAN; PNEUMONIA; TRACHEOBRONCHIAL TOILET;

ANIMALS; BIODEGRADATION, ENVIRONMENTAL; DRUG DELIVERY SYSTEMS; LUNG; MICE; NANOTECHNOLOGY; PARTICLE SIZE; PNEUMONIA;

MURINAE;

EID: 33746355591     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.01.016     Document Type: Article

References (29)

1. Borm P.J. Particle toxicology: from coal mining to nanotechnology. Inhalation Toxicol. 14 (2002) 311-324
2. Brodbeck W.G., Voskerician G., Ziats N.P., Nakayama Y., Matsuda T., and Anderson J.M. In vivo leukocyte cytokine mRNA responses to biomaterials are dependent on surface chemistry. J. Biomed. Mater. Res. 64A (2003) 320-329
3. Brown D.M., Wilson M.R., MacNee W., Stone V., and Donaldson K. Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol. Appl. Pharmacol. 175 (2001) 191-199
4. Brown J.S., Zeman K.L., and Bennett W.D. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am. J. Respir. Crit. Care Med. 166 (2002) 1240-1247
5. Brzoska M., Langer K., Coester C., Loitsch S., Wagner T.O., and Mallinckrodt C. Incorporation of biodegradable nanoparticles into human airway epithelium cells-In vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochem. Biophys. Res. Commun. 318 (2004) 562-570
6. Dailey L.A., Kleemann E., Wittmar M., Gessler T., Schmehl T., Roberts C., Seeger W., and Kissel T. Surfactant-free, biodegradable nanoparticles for aerosol therapy based upon the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm. Res. 20 (2003) 2011-2020
7. Dailey L.A., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., and Kissel T. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J. Controlled Release 86 (2003) 131-144
8. Dasenbrock C., Peters L., Creutzenberg O., and Heinrich U. The carcinogenic potency of carbon particles with and without PAH after repeated intracheal administration in the rat. Toxicol. Lett. 88 (1996) 15-21
9. Driscoll K.E., Carter J.M., Howard B.W., Hassenbein D.G., Pepelko W., Baggs R.B., and Oberdörster G. Pulmonary inflammatory, chemokine, and mutagenic responses in rats after subchronic inhalaton of carbon-black. Toxicol. Appl. Pharmacol. 136 (1996) 372-380
10. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., and Langer R. Large porous particles for pulmonary drug delivery. Science 276 (1997) 1868-1871
11. Evora C., Soriano I., Rogers R.A., Shakesheff K.M., Hanes J., and Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J. Controlled Release 51 (1998) 143-152
12. Ferin J., Oberdorster G., and Penney D.P. Increased pulmonary toxicity of ultrafine particles: 1. Particle clearance, translocation, morphology. J. Aerosol. Sci. 21 (1990) 381-384
13. Fiegel J., Fu J., and Hanes J. Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. J. Controlled Release 96 (2004) 411-423
14. Fink L., Seeger W., Ermert L., Hanze J., Stahl U., Grimminger F., Kummer W., and Bohle RM. Nat. Med. 4 (1998) 1329-1333
15. Grenha A., Seijo B., and Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 25 (2005) 427-437
16. Hamoir J., Nemmar A., Halloy D., Wirth D., Vincke G., Vanderplasschen A., Nemery B., and Gustin P. Effect of polystyrene particles on lung microvascular permeability in isolated perfused rabbit lungs: role of size and surface properties. Toxicol. Appl. Pharmacol. 190 (2003) 278-285
17. Harper G.R., Davis S.S., Davies M.C., Norman M.E., Tadros T.F., Taylor D.C., Irving M.P., Waters J.A., and Watts J.F. Influence of surface coverage with poly(ethylene oxide) an attachment of sterically stabilized microspheres to rat Kupffer cells in vitro. Biomaterials 16 (1995) 427
18. Ibald-Mulli A., Wichmann H.E., Kreyling W., and Peters A. Epidemiological evidence on health effects of ultrafine particles. J. Aerosol. Med. 15 (2002) 189-201
19. Jung T., Breitenbach A., and Kissel T. Sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolides) facilitate the preparation of small negatively charged biodegradable nanospheres. J. Controlled Release 67 (2000) 157-169
20. MacNee W., and Donaldson K. Particulate air pollution: injurious and protective mechanisms in the lungs. In: Holgate S.T., Samet J.M., Koren H.S., and Maynard R.L. (Eds). Air Pollution and Health (1999), Academic Press, London 653-672
21. Möller W., Hofer T., Ziesenis A., Karg E., and Heyder J. Ultrafine particles cause cytoskeletal dysfunctions in macrophages. Toxicol. Appl. Pharmacol. 182 (2002) 197-207
22. Nemmar A., Vanbilloen H., Hoylaerts M.F., Hoet P.H.M., Verbruggen A., and Nemery B. Passage of intratracheally instilled ultrafine particles from the lung into the systemic circulation in hamster. Am. J. Respir. Crit. Care Med. 164 (2001) 1665-1668
23. Nemmar A., Hoylaerts M.F., Hoet P.H.M., Vermylen J., and Nemery B. Size effect of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis. Toxicol. Appl. Pharmacol. 186 (2003) 38-45
24. Niven R.W. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst. 12 (1995) 151-231
25. Oberdörster G. Pulmonary effects of inhaled ultrafine particles. Int. Arch. Occup. Environ. Health 74 (2001) 1-8
26. Oster C.G., Wittmar M., Unger F., Barbu-Tudoran L., Schaper A.K., and Kissel T. Design of amine-modified graft polyesters for effective gene delivery using DNA-loaded nanoparticles. Pharm. Res. 21 (2004) 927-931
27. Renwick L.C., Donaldson K., and Clouter A. Impairment of alveolar macrophage phagocytosis by ultrafine particles. Toxicol. Appl. Pharmacol. 172 (2001) 119-127
28. Tsapis N., Bennett D., Jackson B., Weitz D.A., and Edwards D.A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Nat. Acad. Sci. 99 (2002) 12001-12005
29. Warheit D.B., Hansen J.F., Yuen I.S., Kelly D.P., Snajdr S.I., and Hartsky M.A. Inhalation of high concentrations of low toxicity dusts in rats results in impaired pulmonary clearance mechanisms and persistent inflammation. Toxicol. Appl. Pharmacol. 145 (1997) 10-22